Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: Evidence from a population-based study

Andreas Luchner, John C Jr. Burnett, Michihisa Jougasaki, Hans Werner Hense, G. A J Riegger, Heribert Schunkert

Research output: Contribution to journalArticle

118 Citations (Scopus)

Abstract

Objectives. The present retrospective analysis of data derived from a population-based study examined the relationship between intake of beta- receptor antagonists and plasma concentrations of the cardiac natriuretic peptides and their second messenger. Background. Beta-receptor antagonists are widely used for treatment of cardiovascular disease. In addition to direct effects on heart rate and cardiac Contractility, recent evidence suggests that beta-receptor antagonists may also modulate the cross talk between the sympathetic nervous system and the cardiac natriuretic peptide system. Methods. Plasma concentrations of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and their second messenger cyclic guanosine monophosphate (cGMP) were assessed in addition to anthropometric, hemodynamic and echocardiographic parameters in a population-based sample (n = 672), of which 80 subjects used beta-receptor antagonists. Results. Compared to subjects without medication, subjects receiving beta-receptor antagonists were characterized by substantially elevated ANP, BNP and cGMP plasma concentrations (plus 32%, 89% and 18%, respectively, p < 0.01 each). Analysis of subgroups revealed that this effect was highly consistent and present even in the absence of hypertension, left atrial enlargement, left ventricular hypertrophy or left ventricular dysfunction. The most prominent increase was observed in a subgroup with increased left ventricular mass index. By multivariate analysis, a statistically significant and independent association between betareceptor antagonism and ANP, BNP and cGMP concentrations was confirmed. Such an association could not be demonstrated for other antihypertensive agents such as angiotensin-converting enzyme inhibitors or diuretics. Conclusions. Beta-receptor antagonists appear to augment plasma ANP, BNP and cGMP concentrations. The current observation suggests an important contribution of the cardiac natriuretic peptide system to the therapeutic mechanism of betareceptor antagonists.

Original languageEnglish (US)
Pages (from-to)1839-1844
Number of pages6
JournalJournal of the American College of Cardiology
Volume32
Issue number7
DOIs
StatePublished - Dec 1998

Fingerprint

Natriuretic Peptides
Peptide Receptors
Brain Natriuretic Peptide
Cyclic GMP
Atrial Natriuretic Factor
Second Messenger Systems
Population
Sympathetic Nervous System
Left Ventricular Dysfunction
Left Ventricular Hypertrophy
Angiotensin-Converting Enzyme Inhibitors
Diuretics
Antihypertensive Agents
Cardiovascular Diseases
Multivariate Analysis
Heart Rate
Hemodynamics
Observation
Hypertension
Therapeutics

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism : Evidence from a population-based study. / Luchner, Andreas; Burnett, John C Jr.; Jougasaki, Michihisa; Hense, Hans Werner; Riegger, G. A J; Schunkert, Heribert.

In: Journal of the American College of Cardiology, Vol. 32, No. 7, 12.1998, p. 1839-1844.

Research output: Contribution to journalArticle

Luchner, Andreas ; Burnett, John C Jr. ; Jougasaki, Michihisa ; Hense, Hans Werner ; Riegger, G. A J ; Schunkert, Heribert. / Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism : Evidence from a population-based study. In: Journal of the American College of Cardiology. 1998 ; Vol. 32, No. 7. pp. 1839-1844.
@article{1f1a9b56f0ea4c92b1c51f853068f005,
title = "Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: Evidence from a population-based study",
abstract = "Objectives. The present retrospective analysis of data derived from a population-based study examined the relationship between intake of beta- receptor antagonists and plasma concentrations of the cardiac natriuretic peptides and their second messenger. Background. Beta-receptor antagonists are widely used for treatment of cardiovascular disease. In addition to direct effects on heart rate and cardiac Contractility, recent evidence suggests that beta-receptor antagonists may also modulate the cross talk between the sympathetic nervous system and the cardiac natriuretic peptide system. Methods. Plasma concentrations of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and their second messenger cyclic guanosine monophosphate (cGMP) were assessed in addition to anthropometric, hemodynamic and echocardiographic parameters in a population-based sample (n = 672), of which 80 subjects used beta-receptor antagonists. Results. Compared to subjects without medication, subjects receiving beta-receptor antagonists were characterized by substantially elevated ANP, BNP and cGMP plasma concentrations (plus 32{\%}, 89{\%} and 18{\%}, respectively, p < 0.01 each). Analysis of subgroups revealed that this effect was highly consistent and present even in the absence of hypertension, left atrial enlargement, left ventricular hypertrophy or left ventricular dysfunction. The most prominent increase was observed in a subgroup with increased left ventricular mass index. By multivariate analysis, a statistically significant and independent association between betareceptor antagonism and ANP, BNP and cGMP concentrations was confirmed. Such an association could not be demonstrated for other antihypertensive agents such as angiotensin-converting enzyme inhibitors or diuretics. Conclusions. Beta-receptor antagonists appear to augment plasma ANP, BNP and cGMP concentrations. The current observation suggests an important contribution of the cardiac natriuretic peptide system to the therapeutic mechanism of betareceptor antagonists.",
author = "Andreas Luchner and Burnett, {John C Jr.} and Michihisa Jougasaki and Hense, {Hans Werner} and Riegger, {G. A J} and Heribert Schunkert",
year = "1998",
month = "12",
doi = "10.1016/S0735-1097(98)00478-1",
language = "English (US)",
volume = "32",
pages = "1839--1844",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "7",

}

TY - JOUR

T1 - Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism

T2 - Evidence from a population-based study

AU - Luchner, Andreas

AU - Burnett, John C Jr.

AU - Jougasaki, Michihisa

AU - Hense, Hans Werner

AU - Riegger, G. A J

AU - Schunkert, Heribert

PY - 1998/12

Y1 - 1998/12

N2 - Objectives. The present retrospective analysis of data derived from a population-based study examined the relationship between intake of beta- receptor antagonists and plasma concentrations of the cardiac natriuretic peptides and their second messenger. Background. Beta-receptor antagonists are widely used for treatment of cardiovascular disease. In addition to direct effects on heart rate and cardiac Contractility, recent evidence suggests that beta-receptor antagonists may also modulate the cross talk between the sympathetic nervous system and the cardiac natriuretic peptide system. Methods. Plasma concentrations of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and their second messenger cyclic guanosine monophosphate (cGMP) were assessed in addition to anthropometric, hemodynamic and echocardiographic parameters in a population-based sample (n = 672), of which 80 subjects used beta-receptor antagonists. Results. Compared to subjects without medication, subjects receiving beta-receptor antagonists were characterized by substantially elevated ANP, BNP and cGMP plasma concentrations (plus 32%, 89% and 18%, respectively, p < 0.01 each). Analysis of subgroups revealed that this effect was highly consistent and present even in the absence of hypertension, left atrial enlargement, left ventricular hypertrophy or left ventricular dysfunction. The most prominent increase was observed in a subgroup with increased left ventricular mass index. By multivariate analysis, a statistically significant and independent association between betareceptor antagonism and ANP, BNP and cGMP concentrations was confirmed. Such an association could not be demonstrated for other antihypertensive agents such as angiotensin-converting enzyme inhibitors or diuretics. Conclusions. Beta-receptor antagonists appear to augment plasma ANP, BNP and cGMP concentrations. The current observation suggests an important contribution of the cardiac natriuretic peptide system to the therapeutic mechanism of betareceptor antagonists.

AB - Objectives. The present retrospective analysis of data derived from a population-based study examined the relationship between intake of beta- receptor antagonists and plasma concentrations of the cardiac natriuretic peptides and their second messenger. Background. Beta-receptor antagonists are widely used for treatment of cardiovascular disease. In addition to direct effects on heart rate and cardiac Contractility, recent evidence suggests that beta-receptor antagonists may also modulate the cross talk between the sympathetic nervous system and the cardiac natriuretic peptide system. Methods. Plasma concentrations of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and their second messenger cyclic guanosine monophosphate (cGMP) were assessed in addition to anthropometric, hemodynamic and echocardiographic parameters in a population-based sample (n = 672), of which 80 subjects used beta-receptor antagonists. Results. Compared to subjects without medication, subjects receiving beta-receptor antagonists were characterized by substantially elevated ANP, BNP and cGMP plasma concentrations (plus 32%, 89% and 18%, respectively, p < 0.01 each). Analysis of subgroups revealed that this effect was highly consistent and present even in the absence of hypertension, left atrial enlargement, left ventricular hypertrophy or left ventricular dysfunction. The most prominent increase was observed in a subgroup with increased left ventricular mass index. By multivariate analysis, a statistically significant and independent association between betareceptor antagonism and ANP, BNP and cGMP concentrations was confirmed. Such an association could not be demonstrated for other antihypertensive agents such as angiotensin-converting enzyme inhibitors or diuretics. Conclusions. Beta-receptor antagonists appear to augment plasma ANP, BNP and cGMP concentrations. The current observation suggests an important contribution of the cardiac natriuretic peptide system to the therapeutic mechanism of betareceptor antagonists.

UR - http://www.scopus.com/inward/record.url?scp=0032420652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032420652&partnerID=8YFLogxK

U2 - 10.1016/S0735-1097(98)00478-1

DO - 10.1016/S0735-1097(98)00478-1

M3 - Article

C2 - 9857860

AN - SCOPUS:0032420652

VL - 32

SP - 1839

EP - 1844

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 7

ER -